Kraenzlin ME - Search Results

1

Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.

Sieber P, Lardelli P, Kraenzlin CA, Kraenzlin ME, Meier C. Sieber P, et al. Among authors: kraenzlin me. Clin Drug Investig. 2013 Feb;33(2):117-22. doi: 10.1007/s40261-012-0041-1. Clin Drug Investig. 2013. PMID: 23184667

2

Impact of bisphosphonate wash-out prior to teriparatide therapy in clinical practice.

Keel C, Kraenzlin ME, Kraenzlin CA, Müller B, Meier C. Keel C, et al. Among authors: kraenzlin me, kraenzlin ca. J Bone Miner Metab. 2010;28(1):68-76. doi: 10.1007/s00774-009-0101-7. Epub 2009 Jun 17. J Bone Miner Metab. 2010. PMID: 19633810 Clinical Trial.

3

Possible beneficial effect of bisphosphonates in osteonecrosis of the knee.

Kraenzlin ME, Graf C, Meier C, Kraenzlin C, Friedrich NF. Kraenzlin ME, et al. Among authors: kraenzlin c. Knee Surg Sports Traumatol Arthrosc. 2010 Dec;18(12):1638-44. doi: 10.1007/s00167-010-1106-4. Epub 2010 Apr 8. Knee Surg Sports Traumatol Arthrosc. 2010. PMID: 20376625

4

Effect of ibandronate on spontaneous osteonecrosis of the knee: a randomized, double-blind, placebo-controlled trial.

Meier C, Kraenzlin C, Friederich NF, Wischer T, Grize L, Meier CR, Kraenzlin ME. Meier C, et al. Among authors: kraenzlin me. Osteoporos Int. 2014 Jan;25(1):359-66. doi: 10.1007/s00198-013-2581-5. Epub 2013 Nov 22. Osteoporos Int. 2014. PMID: 24264372 Clinical Trial.

5

Automated HPLC assay for urinary collagen cross-links: effect of age, menopause, and metabolic bone diseases.

Kraenzlin ME, Kraenzlin CA, Meier C, Giunta C, Steinmann B. Kraenzlin ME, et al. Among authors: kraenzlin ca. Clin Chem. 2008 Sep;54(9):1546-53. doi: 10.1373/clinchem.2008.105262. Epub 2008 Jul 24. Clin Chem. 2008. PMID: 18653826 Free article.

6

Risk of fractures with glitazones: a critical review of the evidence to date.

Bodmer M, Meier C, Kraenzlin ME, Meier CR. Bodmer M, et al. Among authors: kraenzlin me. Drug Saf. 2009;32(7):539-47. doi: 10.2165/00002018-200932070-00001. Drug Saf. 2009. PMID: 19530741 Review.

7

Use of depot medroxyprogesterone acetate and fracture risk.

Meier C, Brauchli YB, Jick SS, Kraenzlin ME, Meier CR. Meier C, et al. Among authors: kraenzlin me. J Clin Endocrinol Metab. 2010 Nov;95(11):4909-16. doi: 10.1210/jc.2010-0032. Epub 2010 Aug 4. J Clin Endocrinol Metab. 2010. PMID: 20685865

8

Proton pump inhibitors and fracture risk: true effect or residual confounding?

Bodmer M, Meier C, Kraenzlin ME, Meier CR. Bodmer M, et al. Among authors: kraenzlin me. Drug Saf. 2010 Oct 1;33(10):843-52. doi: 10.2165/11536780-000000000-00000. Drug Saf. 2010. PMID: 20812769 Review.

9

Parathyroid hormone analogues in the treatment of osteoporosis.

Kraenzlin ME, Meier C. Kraenzlin ME, et al. Nat Rev Endocrinol. 2011 Jul 12;7(11):647-56. doi: 10.1038/nrendo.2011.108. Nat Rev Endocrinol. 2011. PMID: 21750510 Review.

10

[Osteoporosis: evaluation, diagnosis and monitoring].

Meier C, Kraenzlin ME. Meier C, et al. Among authors: kraenzlin me. Ther Umsch. 2012 Mar;69(3):145-52. doi: 10.1024/0040-5930/a000267. Ther Umsch. 2012. PMID: 22403107 Review. German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

100 results

Search Page